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Lyme borreliosis, a zoonosis caused by the
spirochete  Borrelia burdorferi sensu lato and
transmitted by Ixodes ticks, is the most prevalent
and widespread vector-borne human infection in
the Northern Hemisphere, with enzootic cycles
that can be maintained in a wide range of ecologic
conditions (1). Reported annual incidence rates
throughout Europe range from 16 cases/100,000
voluntarily reported in France, to 80/100,000 in
seven counties in southern Sweden where the
disease became temporarily reportable in 1992-
93, and 120/100,000 in Slovenia (2), where it is
also reportable. Lyme borreliosis appears to
be rare in the United Kingdom, although
B. burgdorferi s.l. has been detected by polymerase
chain reaction (PCR) in many tick populations and
in archived specimens collected over the last 100
years (3).
The Study
Surveillance for Lyme borreliosis has been
ongoing in England and Wales since September
1986, based mainly on voluntary reporting of
serologically confirmed cases by laboratories to
the Public Health Laboratory Service (PHLS)
Communicable Disease Surveillance Centre
(CDSC)(4). In 1992, the case definition of the
Centers for Disease Control and Prevention
became available (5), and in 1996 a European
case definition came into use (6).  Serologic
diagnosis in the two reference laboratories in
England and Wales follows an internationally
recommended two-step approach (7) of antibody
screening tests followed by immunoblots of
reactive or equivocal samples. Reference labora-
tory serologic tests have improved, with
continuing refinement of immunoblot techniques
and interpretation, as well as introduction of
immunoglobulin (Ig)M tests. Borrelial cultures,
PCR, and genotyping have also been introduced,
mainly for research. Recently, commercial
antibody test kits have become more widely
available, and many diagnostic laboratories now
use them for preliminary screening and send only
reactive samples to reference laboratories for
immunoblot testing. Some kits have IgM
detection components (either singly or in
combination with IgG) and may detect antibody
production at an earlier stage of infection than
previously possible.
Serologically confirmed cases of Lyme
borreliosis should be voluntarily reported to
CDSC by the primary laboratory that referred
the patient’s specimen for confirmation, but
reporting has been incomplete. An enhanced
surveillance scheme was introduced in 1996,
with reference laboratories also reporting to
CDSC. Since 1997 the PHLS reference laboratory
has routinely sent a questionnaire to primary
laboratories seeking information on patient
demographics, clinical features, and tick expo-
sure. This strategy has greatly improved Lyme
borreliosis surveillance, with an 85% return rate
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Figure. Density plot of distribution of indigenously
acquired Lyme borreliosis cases, by county of primary
testing laboratory, England and Wales, 1986-1998.
of questionnaires in the first full year of
implementation. From 1986 to 1992, CDSC
received 227 reports, a mean annual rate of 0.06/
100,000. This rate increased to an average
annual rate of 0.11/100,000 during 1992-1996
(n=235) and to 0.32/100,000 in the first 2 years of
enhanced surveillance (n=334).
The age, sex, and seasonal distribution of
cases were similar in each period. Of the 796
patients, 85 (10.6%) were children < 15 years of
age, 45 (5.7%) were 15-24 years of age, 220
(27.6%) 25-44, 300 (37.7%) 45-64, and 129 (16.2%)
were ≥ 65 years of age; in 17 cases, the patient’s
age was not known. The male:female ratio was
approximately equal in all age groups.
A clear, consistent seasonal pattern was
seen, with 48% of cases reported in the third
quarter of each year.  The peak in laboratory
reports was in September, representing peak
onset of symptoms in early summer. Cases were
reported by laboratories in 68 counties (Figure),
but only 14 counties had more than 10 cases each.
Forty-five percent of reports were of cases in
three contiguous counties in southern England:
219 from Hampshire, 72 from Wiltshire, and 61
from Dorset.  This area includes well-known foci
of Lyme borreliosis in and near the New Forest
and Salisbury Plain. Other counties with a
relatively high number of case reports were
Devon (47 cases) and Somerset (32 cases) in
southwestern England and Norfolk in East
Anglia (29 cases). One hundred eighteen (14.8%)
of the 796 cases were reported to have been
acquired abroad, mainly in the United States,
France, Germany, Austria, and Scandinavia.
Most of these cases occurred in vacationers.
Forty-six (5.8%) cases were apparently acquired
occupationally: nine through work with or
hunting of deer, seven through forestry work,
three through farm work, one through exposure
during tick ecology studies, and another through
work as a veterinary surgeon. For the others,
occupational details were not reported. The
proportion of Lyme borreliosis patients with a
reported history of tick bites has risen steadily,
from 24% in 1986-1992 and 32% in 1993-1996 to
39% in 1997-98. Other patients (30%, 34% and
42% in the corresponding periods) gave histories
of insect bites and may not have distinguished
between insects and ticks.
Clinical features (Table) reported over the
13-year period include neuroborreliosis (facial
palsy, radiculopathy, meningitis, and “neurobor-
reliosis”) and nonspecific neurologic symptoms
(e.g., fatigue, malaise, and headache). Neurobor-
relosis was reported in 23% (21/91) of patients
≤  14 years of age, compared with 14% (96/701) in
other age groups (x2 = 5.6, p = 0.02), a difference
explained by a higher reported incidence of
isolated facial palsy in children.
Musculoskeletal symptoms have been di-
vided into “arthritis” and “other,” which includes
arthralgia and myalgia. Arthritis was reported in
9 (20%) of 45 patients 15-24 years of age,
compared with 22 (3%) of 746 patients in other
age groups (x2 = 28.5; p < 0.001). The proportions
of cases associated with both a tick bite and
erythema migrans increased from 12% in 1986-
1992 to 22% in 1997-98. Only three cases of
acrodermatitis chronica atrophicans were re-
ported, and cardiac involvement was reported in
only five cases.
Arthritis was reported in 6 (14%) of 42 cases
acquired in the United States, compared with
none of 8 Scandinavian cases, 1 of 55 other
European cases, and none of 47 New Forest cases
(U.S. vs. other odds ratio [OR] = 18; 95%
confidence interval [CI] 2-835; Fisher’s exact p =Dispatches
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Table. Clinical features reported in 796 patients with Lyme borreliosis, England and Wales, 1986–1998
1986-1992 1993-1996 1997-98 Total
No. (%) No. (%) No. (%) No. (%)
Total reportsa 227 (100) 235 (100) 334 (100) 796 (100)
Any insect bite   67   (30)   79   (34) 140   (42) 286   (36)
Tick bite   53   (23)   74   (32) 128   (38) 255   (32)
Arthritis   16     (7)     5     (2)   11     (3)   32     (4)
Other musculo- skeletal symptoms   58   (26)   31   (13)   49   (15) 138   (17)
Skin involvement   80   (35) 125   (53) 204   (61) 409   (51)
Erythema migrans   64   (28)   97   (41) 164   (49) 325   (41)
Erythema migrans & tick bite   27   (12)   41   (17)   72   (22) 140   (18)
Neuroborreliosis   47   (21)   28   (12)   43   (13) 118   (15)
Other neurologic symptoms   46   (20)   16     (7)   20     (6)   82   (10)
Cardiac involvement     2  (0.9)     1  (0.4)     2  (0.6)     5  (0.6)
aPatients may have multiple exposures/symptoms.
0.001). Neuroborreliosis was reported in 6 (14%)
of 42 U.S.-acquired cases, none of 8 Scandinavian
cases, 6 (11%) of 55 other European cases, and 12
(26%) of 47 New Forest cases. Erythema migrans
was reported in 13 (31%) of 42 U.S.-acquired
cases, 7 (88%) of the 8 Scandinavian cases, 21
(38%) of 55 other European cases, and 28 (60%) of
47 New Forest cases (U.S. v other OR = 0.26; CI =
0.11-0.58; x2 = 11.8; p <0.001).
Conclusions
The large increase in Lyme disease incidence
in 1997 and 1998 may represent a surveillance
artefact resulting from increased awareness of
the disease, greater access to diagnostic facilities,
more sensitive diagnostic methods, and more
complete reporting to CDSC. Awareness of the
infection has increased rapidly as a result of
media interest and ready access to medical
information from Internet sources. However,
Lyme borreliosis is probably not as widely
recognized in the United Kingdom as in some
other European countries (8). Enhanced long-
term surveillance and additional cross-checking
between the PHLS reference laboratory and
CDSC are needed to allow detection of the time
trends in disease incidence. The apparent
widening of the geographic areas reporting cases
is probably due to improved reporting, but
current surveillance data indicate areas with
high disease incidence from recreational and
occupational exposures.
Population surveillance has clarified the
clinical manifestations of Lyme borreliosis in
England and Wales. However, the proportion of
patients with erythema migrans may be
relatively low, either because patients with
erythema migrans are easily identified without
serologic tests or because serologic tests have
relatively low sensitivity at this early stage. This
underreporting could bias reporting towards a
higher proportion of the more complicated later-
stage infections (2) or those with atypical acute
symptoms.
Differences between clinical symptoms in the
United States and Europe have been attributed
to differences in prevalence of B. burgdorferi
genospecies. In the United States, B. burgdorferi
sensu stricto predominates, with an associated
pattern of musculoskeletal complications. Thus,
patients with U.S.-acquired infections had a
higher rate of arthritis than those whose cases
were acquired in mainland Europe. In Europe, at
least two other pathogenic genospecies are found
in addition to B. burgdorferi s.s.: B. afzelii, which
is associated with skin manifestations, and
B. garinii, which is associated with neurologic
complications (9). Another strain, B. valaisiana,
does not appear to be associated with manifesta-
tions of disseminated borreliosis. These genospecies
have been identified in British tick populations,
consistent with the broad range of clinical
presentations seen in the United Kingdom. The
relatively high prevalence of the apparently less
pathogenic B. valaisiana in some British tick
populations may be a factor in the low incidence
of Lyme borreliosis observed in the United
Kingdom.
    Both the prevalence of B. burgdorferi-infected
ticks and the incidence of Lyme borreliosis are
highest in eastern Europe and decrease
westward across the continent, including theDispatches
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British Isles (2). Throughout Europe, heterog-
enous deciduous woodlands provide favorable
ecologic conditions for host species that maintain
both ticks and spirochetes (10), and the high-
incidence areas in the United Kingdom conform
to this description. However, the distribution of
infected ticks is far wider than that of reported
human cases, and Lyme borreliosis is an
important potential emerging zoonosis in
England and Wales.  Factors that could increase
incidence include changing patterns of land use,
especially for recreation, and changes in the
density of animals that act as reservoir hosts.
Climatic factors such as drought or prolonged
cold weather can substantially affect tick
populations and their level of activity, which may
be reflected in fluctuations in the incidence of
Lyme borreliosis (11).
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